Pediatric ECMO: unfavorable outcomes are associated with inflammation and endothelial activation

Sherrill D Caprarola1, Derek K Ng2, Megan K Carroll2

  • 1Department of Pediatrics, Division of Pediatric Cardiac Critical Care, Children's National Health System, Washington, DC, USA.

Pediatric Research
|November 4, 2021
PubMed

Insights

High levels of inflammatory and endothelial activation markers in children on extracorporeal membrane oxygenation (ECMO) correlate with mortality and abnormal neuroimaging. These findings highlight potential biomarkers for risk stratification in pediatric ECMO patients.

Area of Science:

  • Pediatric Critical Care Medicine
  • Cardiovascular Research
  • Biomarker Discovery

Background:

  • Extracorporeal membrane oxygenation (ECMO) support in children can trigger inflammatory and endothelial activation responses.
  • Understanding these responses is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the association between circulating inflammatory, endothelial activation, and fibrinolytic markers and mortality in pediatric ECMO patients.
  • To determine if these markers correlate with neurologic outcomes in children undergoing ECMO.

Main Methods:

  • Secondary analysis of a prospective observational study involving 99 pediatric ECMO patients.
  • Measurement of inflammatory (IFNγ, IL-6, IL-1β, TNFα), endothelial activation (E-selectin, P-selectin, ICAM-3, TM), and fibrinolytic (tPA, PAI-1) markers in plasma during ECMO support.

Main Results:

  • Elevated inflammatory biomarkers on ECMO day 1 were associated with abnormal neuroimaging.
  • Higher ECMO day 1 and peak levels of IL-6 and PAI-1 were observed in non-survivors.
  • No significant association was found between tested biomarkers and long-term neurobehavioral outcomes.

Conclusions:

  • Circulating inflammatory, endothelial activation, and fibrinolytic markers are linked to mortality and abnormal neuroimaging in pediatric ECMO patients.
  • A proinflammatory and prothrombotic profile is significantly associated with mortality in multivariable models.
  • Further research is needed to identify specific profiles associated with neurologic injury and mortality risk.
Abstract

Related Concept Videos

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.0K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.3K
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
63
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
428